查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1362919

血紅素病市場規模、佔有率、趨勢分析報告：按類型、診斷、治療、區域、細分趨勢，2023-2030

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Diagnosis, By Therapy, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

血紅蛋白病市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球血紅素病市場規模預計將達到207億美元，2023年至2030年年複合成長率為12.6%。

由於鐮狀細胞疾病（SCD）和地中海貧血等疾病的患病不斷增加，該市場正在穩步成長。促進因素包括診斷技術的進步、意識的提高和醫療基礎設施的改善。此外，創新治療方法的發展和政府配合措施也有助於市場擴張。

近年來，鐮狀細胞疾病的診斷技術有了顯著進展。一個顯著的趨勢是擴大使用分子遺傳學檢測，特別是 DNA 分析，來鑒定與鐮狀細胞疾病相關的特定突變。這種方法可以進行精確和準確的診斷，使醫療專業人員能夠確定個體是否存在鐮狀細胞性狀或 SCD。此外，技術進步促進了即時檢查裝置的發展，可以在資源有限的環境中進行快速篩選和診斷。診斷技術的這些進步不僅有利於早期發現和早期療育，而且有利於那些有遺傳性鐮狀細胞疾病風險的人的遺傳諮詢和計劃生育。

近年來，血紅蛋白疾病（包括 SCD 和地中海貧血）的治療進展顯示出有希望的趨勢。基因治療方法的開發和利用是市場的普遍普及之一。基因療法旨在透過將功能基因引入罹患的細胞來糾正導致這些疾病的基因突變。多項成功的臨床試驗表明，疾病症狀顯著改善，患者輸血依賴性降低。此外，CRISPR-Cas9等基因編輯技術的出現具有精確糾正患者自身細胞內缺陷基因的巨大潛力。這種創新方法在臨床前研究中顯示出有希望的結果，並可能在不久的將來為血紅蛋白疾病提供一種根治性選擇。此外，支持治療的進步，例如輸血方案、鐵螯合療法和幹細胞移植技術的改進，繼續有助於改善血紅蛋白疾病患者的預後。

增加用於開發治療血紅蛋白病的新治療方法的投資和資金籌措預計將在預測期內進一步推動市場成長。例如，2023 年 5 月，美國參議員提出了 Sickle 法案，該法案將為改善越來越多鐮狀細胞疾病患者的生活品質的服務提供資金，並為治療鐮狀細胞疾病的醫務人員提供支持。我們已提交了Cell護理擴展法。此外，布朗克斯血液研究基金會 (BBRF) 等私人資金為地中海貧血和其他血紅蛋白疾病的研究和管理提供了基礎。

治療成本急劇上升可能會對市場產生負面影響。例如，美國美國衛生研究院的一項新研究表明，64 歲以下患有鐮狀細胞疾病的美國人在一生中患鐮狀細胞疾病的幾率比沒有鐮狀細胞疾病的人要低。這些醫療費用大約多出44,000 美元。此外，保險公司平均為每位鐮狀細胞疾病患者支付 170 萬美元。

血紅蛋白病市場報告亮點

  • 在2022年的血紅蛋白疾病市場中，鐮狀細胞疾病細分市場佔據最大佔有率，達到58.6%，預計在預測期內將以最快的速度成長。這是由生物製藥公司和非營利組織越來越多致力於改善鐮狀細胞疾病治療機會的舉措所推動的。
  • 由於北美和歐洲的高診斷率，鐮狀細胞診斷領域在血紅蛋白疾病市場佔據主導地位，到2022年將佔50.5%的佔有率。
  • 依治療方法分類，鐮狀細胞疾病領域佔最大銷售佔有率，2022年為62.1%。廣泛的研究加上政府資助開發治療鐮狀細胞疾病的新治療方法是促進該領域發展的主要要素。
  • 收益佔有率%。
  • 預計亞太地區在預測期內將呈現最快的成長率。鐮狀細胞疾病和地中海貧血罹患的高盛行率預計將推動未來年度的市場成長。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • 新型冠狀病毒感染疾病（COVID-19）影響分析

第4章 業務分析的類型

  • 血紅素病市場：類型變異分析
  • 地中海型貧血
  • 鐮狀細胞疾病
  • 血紅素變異體

第5章 診斷業務分析

  • 血紅素病市場：診斷波動分析
  • 地中海型貧血
  • 鐮狀細胞疾病
  • 血紅素變異體

第6章 治療業務分析

  • 血紅素病市場：治療變異分析
  • 地中海型貧血
  • 鐮狀細胞疾病
  • 血紅素變異體

第7章 區域業務分析

  • 2022 年和 2030 年按地區分類的血紅素病市場佔有率
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭形勢

  • 參與企業
    • Sangamo Therapeutics
    • Bluebird bio, Inc.
    • Global Blood Therapeutics, Inc
    • Pfizer, Inc.
    • Emmaus Life Sciences, Inc.
    • Prolong Pharmaceuticals, LLC
    • Celgene Corporation (BMS)
    • Bioverativ, Inc. (Sanofi)
    • Gamida Cell
    • Novartis AG
  • 參與企業概況
  • 財務實績
  • 產品基準評效
  • 2022 年公司市場佔有率分析
  • 策略規劃

第9章 分析師的觀點

Product Code: 978-1-68038-736-0

Hemoglobinopathies Market Growth & Trends:

The global hemoglobinopathies market size is expected to reach USD 20.70 billion by 2030 and is expected to expand at a CAGR of 12.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is experiencing steady growth due to increasing prevalence of disorders like sickle cell disease (SCD) and thalassemia. The driving factors include advancements in diagnostic techniques, growing awareness, and improving healthcare infrastructure. Additionally, the development of innovative therapies and government initiatives are contributing to market expansion.

In recent years, there have been significant advancements in diagnostic techniques for sickle cell disease. One prominent trend is the increased utilization of molecular genetic testing, specifically DNA analysis, to identify specific mutations associated with the disease. This approach allows for precise and accurate diagnosis, enabling healthcare professionals to determine the presence of sickle cell trait or SCD in individuals. Additionally, technological advancements have led to the development of point-of-care testing devices, enabling rapid screening and diagnosis in resource-limited settings. These advancements in diagnostic techniques not only enhance early detection and intervention but also facilitate genetic counseling and family planning for individuals at risk of passing on the disease.

Advancements in therapy for hemoglobinopathies, including SCD and thalassemia, have shown promising trends in recent years. Development and utilization of gene therapy approaches is one of the prevalent trend in the market. Gene therapy aims to correct the genetic mutations responsible for these conditions by introducing functional genes into affected cells. Several successful clinical trials have demonstrated significant improvements in disease symptoms and reduced transfusion dependence in patients. Additionally, the emergence of gene editing techniques, such as CRISPR-Cas9, holds great potential for precisely modifying faulty genes in a patient's own cells. This innovative approach has shown promising results in preclinical studies and may offer a curative option for hemoglobinopathies in the near future. Furthermore, advancements in supportive care, including transfusion protocols, iron chelation therapy, and improved stem cell transplantation techniques, continue to contribute to enhanced outcomes for patients with hemoglobinopathies.

An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies will further boost the market growth over the forecast period. For instance, in May 2023, U.S. Senators introduced the Sickle Cell Care Expansion Act, legislation to offer funding for services to advance the quality of life for the growing number of patients living with Sickle Cell and support the medical staff that treats sickle cell disease. Furthermore, private funding such as the Bronx Blood Research Fund (BBRF) provides a platform for research and management of thalassemia and other hemoglobinopathies.

High cost of treatment might an adverse impact on the market. For instance, according to new research supported by the National Institutes of Health, living with sickle cell disease costs Americans ages 64 and under with commercial health insurance about USD 44,000 more in out-of-pocket medical expenses over their lifetimes than people without the condition. Additionally, insurers shell out an average of USD 1.7 million for each sickle cell disease patient.

Hemoglobinopathies Market Report Highlights:

  • The sickle cell disease segment held the largest share of 58.6% in 2022 of the hemoglobinopathies market and is expected to grow at the fastest rate during the forecast period. This is attributed to growing initiatives by biopharmaceutical companies and nonprofit organizations focused on improving access to SCD treatment
  • The sickle cell disease diagnosis segment dominated the hemoglobinopathies market and accounted for a 50.5% share in 2022 owing to high diagnostic rates in North America and Europe
  • By therapy, the sickle cell disease segment held the largest revenue share of 62.1% in 2022. Extensive research coupled with government funding for the development of novel therapies for treating the disorder is the major factor contributing to the segment growth
  • North America held the largest revenue share of 37.7% in 2022 owing to increasing awareness of hemoglobinopathies, improving healthcare facilities and launch of new products in the region are the major factor augmenting the regional growth
  • Asia Pacific is estimated to exhibit the fastest growth rate over the forecast period. The presence of a large number of patients suffering from sickle cell disease and thalassemia is expected to propel market growth in the coming years
  • Major players in the market are Sangamo Therapeutics, bluebird bio, Inc., Global Blood Therapeutics, Inc., Pfizer, Inc., Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, LLC, Celgene Corporation, Bioverativ Inc., Gamida Cell and Novartis AG

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type segment
      • 1.1.1.2. Diagnosis segment
      • 1.1.1.3. Therapy segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type Snapshot
  • 2.3. Diagnosis and Therapy Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of hemoglobinopathies in under - developed countries
      • 3.2.1.2. High unmet needs
      • 3.2.1.3. Increasing R&D investments
      • 3.2.1.4. Initiatives to improve disease awareness levels
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of healthcare infrastructure
      • 3.2.2.2. High cost of treatment
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID - 19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Hemoglobinopathies Market: Type Movement Analysis
  • 4.2. Thalassemia
    • 4.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
  • 4.3. Sickle Cell Disease
    • 4.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 4.4. Hb Variants
    • 4.4.1. Hb Variants Market, 2018 - 2030 (USD Million)

Chapter 5. Diagnosis Business Analysis

  • 5.1. Hemoglobinopathies Market: Diagnosis Movement Analysis
  • 5.2. Thalassemia
    • 5.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
  • 5.3. Sickle Cell Disease
    • 5.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 5.4. Hb Variants
    • 5.4.1. Hb Variants Market, 2018 - 2030 (USD Million)

Chapter 6. Therapy Business Analysis

  • 6.1. Hemoglobinopathies Market: Therapy Movement Analysis
  • 6.2. Thalassemia
    • 6.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
  • 6.3. Sickle Cell Disease
    • 6.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4. Other Hb Variants
    • 6.4.1. Other Hb Variants Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Hemoglobinopathies Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. SWOT Analysis
    • 7.2.2. North America Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.2.3. U.S.
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. U.S. Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.2.4. Canada
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Canada Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. UK Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Germany Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. France Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Italy Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Spain Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Denmark Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Sweden Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Norway Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.10. Russia
      • 7.3.10.1. Key Country Dynamics
      • 7.3.10.2. Target Disease Prevalence
      • 7.3.10.3. Competitive Scenario
      • 7.3.10.4. Regulatory Framework
      • 7.3.10.5. Russia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Japan Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. China Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. India Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Australia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Thailand Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. South Korea Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.8. Singapore
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Target Disease Prevalence
      • 7.4.8.3. Competitive Scenario
      • 7.4.8.4. Regulatory Framework
      • 7.4.8.5. Singapore Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Brazil Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Mexico Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Argentina Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. South Africa Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Saudi Arabia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. UAE Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Kuwait Hemoglobinopathies Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
    • 8.1.1. Sangamo Therapeutics
      • 8.1.1.1. Overview
      • 8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.1.3. Product Benchmarking
      • 8.1.1.4. Strategic Initiatives
    • 8.1.2. Bluebird bio, Inc.
      • 8.1.2.1. Overview
      • 8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.2.3. Product Benchmarking
      • 8.1.2.4. Strategic Initiatives
    • 8.1.3. Global Blood Therapeutics, Inc
      • 8.1.3.1. Overview
      • 8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.3.3. Product Benchmarking
      • 8.1.3.4. Strategic Initiatives
    • 8.1.4. Pfizer, Inc.
      • 8.1.4.1. Overview
      • 8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.4.3. Product Benchmarking
      • 8.1.4.4. Strategic Initiatives
    • 8.1.5. Emmaus Life Sciences, Inc.
      • 8.1.5.1. Overview
      • 8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.5.3. Product Benchmarking
      • 8.1.5.4. Strategic Initiatives
    • 8.1.6. Prolong Pharmaceuticals, LLC
      • 8.1.6.1. Overview
      • 8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.6.3. Product Benchmarking
      • 8.1.6.4. Strategic Initiatives
    • 8.1.7. Celgene Corporation (BMS)
      • 8.1.7.1. Overview
      • 8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.7.3. Product Benchmarking
      • 8.1.7.4. Strategic Initiatives
    • 8.1.8. Bioverativ, Inc. (Sanofi)
      • 8.1.8.1. Overview
      • 8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.8.3. Product Benchmarking
      • 8.1.8.4. Strategic Initiatives
    • 8.1.9. Gamida Cell
      • 8.1.9.1. Overview
      • 8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.9.3. Product Benchmarking
      • 8.1.9.4. Strategic Initiatives
    • 8.1.10. Novartis AG
      • 8.1.10.1. Overview
      • 8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.10.3. Product Benchmarking
      • 8.1.10.4. Strategic Initiatives
  • 8.2. Participant's Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Company Market Share Analysis, 2022
  • 8.6. Strategy Mapping
    • 8.6.1. Expansion
    • 8.6.2. Acquisition
    • 8.6.3. Product/Service Launch
    • 8.6.4. Others

Chapter 9. Analyst View

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 4 Global hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 5 Global hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 6 Global hemoglobinopathies market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 9 North America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 10 North America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 13 U.S. hemoglobinopathies Market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 Canada hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 15 Canada hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 16 Canada hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 17 Europe hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 18 Europe hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 19 Europe hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 20 Europe hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 21 UK hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 22 UK hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 23 UK hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 24 Germany hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 25 Germany hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 26 Germany hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 27 France hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 28 France hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 29 France hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 30 Italy hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 31 Italy hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 32 Italy hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 33 Spain hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 34 Spain hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 35 Spain hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 36 Denmark hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 37 Denmark hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 38 Denmark hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 39 Sweden hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 40 Sweden hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 41 Sweden hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 42 Norway hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 43 Norway hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 44 Norway hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 49 Japan hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 50 Japan hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 51 Japan hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 52 China hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 53 China hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 54 China hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 55 India hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 56 India hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 57 India hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 58 South Korea hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 59 South Korea hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 60 South Korea hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 61 Australia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 62 Australia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 63 Australia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 64 Singapore hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 65 Singapore hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 66 Singapore hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 67 Thailand hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 68 Thailand hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 69 Thailand hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 70 Latin America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 72 Latin America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 73 Latin America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 74 Brazil hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 75 Brazil hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 76 Brazil hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 77 Mexico hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 78 Mexico hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 79 Mexico hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 80 Argentina hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 81 Argentina hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 82 Argentina hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 87 South Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 88 South Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 89 South Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 90 UAE hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 91 UAE hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 92 UAE hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 96 Kuwait hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 97 Kuwait hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 98 Kuwait hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 99 Company Overview
  • Table 100 Financial Performance
  • Table 101 Product Benchmarking
  • Table 102 Strategic Initiatives

List of Figures

  • Fig. 1 Hemoglobinopathies market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain - based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hemoglobinopathies market segmentation
  • Fig. 9 Market snapshot, 2022
  • Fig. 10 Market trends & outlook
  • Fig. 11 Market driver relevance analysis (current & future impact)
  • Fig. 12 Market restraint relevance analysis (current & future impact)
  • Fig. 13 PESTEL analysis
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Global Hemoglobinopathies market: Type movement analysis
  • Fig. 16 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
  • Fig. 17 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
  • Fig. 18 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
  • Fig. 19 Global Hemoglobinopathies market: Diagnosis movement analysis
  • Fig. 20 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
  • Fig. 21 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
  • Fig. 22 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
  • Fig. 23 Global Hemoglobinopathies market: Therapy movement analysis
  • Fig. 24 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
  • Fig. 25 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
  • Fig. 26 Global Hemoglobinopathies market, for other Hb variants, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional outlook, 2022 & 2030
  • Fig. 29 Global Hemoglobinopathies market: Region movement analysis
  • Fig. 30 North America Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 35 UK Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 36 France Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 44 China Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 45 India Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 49 Singapore Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait Hemoglobinopathies market, 2018 - 2030 (USD Million)